aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. It is also developing ATYR1940, a therapeutic candidate based on a protein naturally secreted from muscle for the treatment of facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, and duchenne muscular dystrophy. aTyr Pharma, Inc. has collaboration with the University of Nebraska Medical Center to advance neuropilin-2 biology and therapeutic opportunities for ATYR1923. The company was founded in 2005 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone858-731-8389
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees65
Next Earnings Date3/18/2019 (Estimated)
OptionableOptionable
aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions
What is aTyr Pharma's stock symbol?
aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."
How were aTyr Pharma's earnings last quarter?
aTyr Pharma Inc (NASDAQ:LIFE) posted its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.34) by $0.01. View aTyr Pharma's Earnings History.
When is aTyr Pharma's next earnings date?
What price target have analysts set for LIFE?
3 analysts have issued 12 month target prices for aTyr Pharma's shares. Their forecasts range from $0.75 to $1.80. On average, they expect aTyr Pharma's share price to reach $1.1833 in the next twelve months. This suggests a possible upside of 134.5% from the stock's current price. View Analyst Price Targets for aTyr Pharma.
What is the consensus analysts' recommendation for aTyr Pharma?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for aTyr Pharma.
Has aTyr Pharma been receiving favorable news coverage?
News coverage about LIFE stock has been trending somewhat positive this week, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. aTyr Pharma earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the near term.
Who are some of aTyr Pharma's key competitors?
Some companies that are related to aTyr Pharma include Proteon Therapeutics (PRTO), Oncobiologics (ONS), Entera Bio (ENTX), Genocea Biosciences (GNCA), Microbot Medical (MBOT), Curis (CRIS), Arsanis (ASNS), BIONDVAX PHARMA/S (BVXV), TRACON Pharmaceuticals (TCON), Vical (VICL), CytRx (CYTR), Titan Pharmaceuticals (TTNP), Windtree Therapeutics (WINT), Aevi Genomic Medicine (GNMX) and Genetic Technologies (GENE).
What other stocks do shareholders of aTyr Pharma own?
Who are aTyr Pharma's key executives?
aTyr Pharma's management team includes the folowing people:
- Dr. Sanjay S. Shukla, Pres, CEO & Director (Age 47)
- Dr. David J. King, Scientific Consultant (Age 60)
- Dr. John D. Mendlein, Strategic Advisor & Director (Age 59)
- Dr. Sanuj K. Ravindran, Bus. Advisor (Age 47)
- Xiang-Lei Yang Ph.D., Founder
When did aTyr Pharma IPO?
(LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.
Who are aTyr Pharma's major shareholders?
aTyr Pharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (0.62%). Company insiders that own aTyr Pharma stock include Ashraf Amanullah, Ecor1 Capital Fund Qualified,, Jill Marie Broadfoot, John Mendlein and Paul Schimmel. View Institutional Ownership Trends for aTyr Pharma.
Which institutional investors are selling aTyr Pharma stock?
How do I buy shares of aTyr Pharma?
Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is aTyr Pharma's stock price today?
One share of LIFE stock can currently be purchased for approximately $0.5047.
How big of a company is aTyr Pharma?
aTyr Pharma has a market capitalization of $15.15 million. The biotechnology company earns $-48,200,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. aTyr Pharma employs 65 workers across the globe.
What is aTyr Pharma's official website?
How can I contact aTyr Pharma?
aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-731-8389 or via email at [email protected]
MarketBeat Community Rating for aTyr Pharma (NASDAQ LIFE)
MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote "Outperform" if you believe LIFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
